Meeting Banner
Abstract #1842

Development and external validation of IMPROD biparametric MRI-based nomogram for the prediction of prostate biopsy outcome in men with a clinical suspicion of prostate cancer (IMPROD and MULTI-IMPROD trials, #opensourcetrial)

Ivan Jambor1,2, Ileana Montoya Perez1, Janne Verho1, Otto Ettala3, Juha Knaapila3, Pekka Taimen1, Kari Syvänen3, Aida Kiviniemi1, Esa Kähkönen3, Marjo Seppänen4, Antti Rannikko5, Outi Oksanen5, Jarno Riikonen6, Sanna-Mari Vimpeli6, Tommi Kauko3, Harri Merisaari1, Tapio Pahikkala1, Markku Kallajoki3, Tuomas Mirtti7, Jani Saunavaara3, Peter J Boström3, and Hannu Aronen1

1University of Turku, Turku, Finland, 2Icahn School of Medicine at Mount Sinai, New York, NY, United States, 3Turku University Hospital, Turku, Finland, 4Satakunta Central Hospital, Pori, Finland, 5Helsinki University Hospital, Helsinki, Finland, 6Tampere University Hospital, Tampere, Finland, 7University of Helsinki, Helsinki, Finland

Nomograms for prediction of prostate biopsy outcomes incorporating qualitative and quantitative findings of IMPROD biparametric MRI (IMPROD bpMRI consists of T2 weighted imaging and three separate DWI acquisitions) were developed using data of 161 men enrolled as a part of the single-institutional IMPROD (NCT01864135) trial and externally validated in 338 men enrolled as a part of the multi-institutional MULTI-IMPROD(NCT02241122) trial. A nomogram using IMPROD bpMRI findings had area under the curve values (95% confidence interval) of 0.92 (0.88-0.96), and 0.88 (0.84-0.92) in the development and validation cohorts, respectively, for the detection of prostate cancer with Gleason score 3+4 or higher.

This abstract and the presentation materials are available to members only; a login is required.

Join Here